The Lancet Diabetes and Endocrinology : Impact Factor & More
eISSN: 2213-8595pISSN: 2213-8587
Share this on:
Key Metrics
CiteScore 
49.2
Impact Factor
>= 25
Scite Index
0.88 5-Year SI
SNIP
9
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
The Lancet Diabetes and Endocrinology Journal Specifications
| Overview | |
| Publisher | ELSEVIER SCIENCE INC |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 2013 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in The Lancet Diabetes and Endocrinology ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in The Lancet Diabetes and Endocrinology
Diabetes-related complications: an evolving spectrum.
- 1 Jun 2026
- The lancet. Diabetes & endocrinology
Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.
- 1 Jun 2026
- The lancet. Diabetes & endocrinology
A conceptual framework for modernising and right-sizing global diabetes care.
- 1 Jun 2026
- The lancet. Diabetes & endocrinology
Correction to Lancet Diabetes Endocrinol 2025; 13: 935-48.
- 1 Jun 2026
- The lancet. Diabetes & endocrinology
What REDEFINE 5 signals for obesity trials in Asia and beyond.
- 1 Jun 2026
- The lancet. Diabetes & endocrinology
What is an optimal serum thyroid-stimulating hormone value in older adults?
- 1 Jun 2026
- The lancet. Diabetes & endocrinology
Diabetes-related complications: an evolving spectrum.
- 1 Jun 2026
- The lancet. Diabetes & endocrinology
Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.
- 1 Jun 2026
- The lancet. Diabetes & endocrinology
A conceptual framework for modernising and right-sizing global diabetes care.
- 1 Jun 2026
- The lancet. Diabetes & endocrinology
Correction to Lancet Diabetes Endocrinol 2025; 13: 935-48.
- 1 Jun 2026
- The lancet. Diabetes & endocrinology
What REDEFINE 5 signals for obesity trials in Asia and beyond.
- 1 Jun 2026
- The lancet. Diabetes & endocrinology
What is an optimal serum thyroid-stimulating hormone value in older adults?
- 1 Jun 2026
- The lancet. Diabetes & endocrinology
FAQs on The Lancet Diabetes and Endocrinology
How long has The Lancet Diabetes and Endocrinology been actively publishing? 
What is the publishing frequency of The Lancet Diabetes and Endocrinology?
How many articles did The Lancet Diabetes and Endocrinology publish last year?
What is the eISSN & pISSN for The Lancet Diabetes and Endocrinology?
What is Citescore for The Lancet Diabetes and Endocrinology?
What is SNIP score for The Lancet Diabetes and Endocrinology?
Who is the publisher of The Lancet Diabetes and Endocrinology?
